Vetbiobank, a specialist in animal biotherapies, becomes the first veterinary pharmaceutical company in France to receive GMP certification for its pharmaceutical manufacturing activities.
Vetbiobank has thus reached a new milestone towards obtaining the first MA for its veterinary drug based on canine neonatal stem cells against osteoarthritis in dogs.
Vetbiobank becomes one of the first laboratory to obtain this certification for a patented 3D bioproduction process, in a bioreactor, capable of efficiently meeting the needs of these mass markets.
